Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | BACE1 | P56817 | 4/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4923558 | 0.89 | ALDH1A1 (0.52) | L3MBTL1ALDH1A1TDP1BACE1CYP2D6 | |
| SCHEMBL4923702 | 0.85 | L3MBTL1 (0.49) | L3MBTL1ALDH1A1TDP1BACE1CYP2D6 | |
| SCHEMBL4930910 | 0.82 | ACHE (0.62) | L3MBTL1ALDH1A1CYP2D6DRD3CYP1A2 | |
| SCHEMBL4933690 | 0.82 | DRD3 (0.49) | L3MBTL1ALDH1A1TDP1BACE1CYP2D6 | |
| SCHEMBL4925214 | 0.81 | DRD3 (0.60) | L3MBTL1ALDH1A1BACE1DRD3KDM4E | |
| SCHEMBL4925910 | 0.79 | DRD3 (0.51) | L3MBTL1ALDH1A1BACE1DRD3KDM4E | |
| SCHEMBL29373213 | 0.76 | MEN1 (0.61) | L3MBTL1ALDH1A1DRD3MEN1KMT2A | |
| SCHEMBL4922627 | 0.74 | DRD3 (0.63) | TDP1CYP2D6CYP2C19DRD3MEN1 | |
| SCHEMBL31642250 | 0.74 | TSHR (0.63) | L3MBTL1ALDH1A1TDP1CYP2D6CYP2C19 | |
| SCHEMBL791880 | 0.73 | DRD3 (0.61) | TDP1CYP2D6CYP2C19DRD3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076774-A1 | Kinase Modulators and Methods of Use | EXELIXIS, INC. (US) | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076774-A1 | Kinase Modulators and Methods of Use | AKT3, RPS6KA3, CDK3 | L3MBTL1 2400/4885ALDH1A1 4305/4885TDP1 2249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.